There’s Only One Ozempic

Novo Nordisk today announced the launch of a new consumer campaign for Ozempic® (semaglutide) injection 0.5 mg, 1 mg, and 2 mg, reinventing how traditional pharma advertising is being done. The campaign features the celebrated comedy pairing of actors Justin Long and John Hodgman, who first appeared together in a series of popular TV commercials in the mid-2000s. In this new campaign the duo combine levity, lively banter, and everyday moments to encourage informed and impactful dialogue between people living with type 2 diabetes and their doctors about GLP-1 treatment options.

While Ozempic® is now a household name, by taking this unique, patient-focused approach, the campaign aims to educate on all the FDA-approved uses for Ozempic® and how this differentiates this iconic brand from other GLP-1s for the treatment of type 2 diabetes and unapproved compounded “semaglutide.”

“Not all GLP-1s are the same, and people with type 2 diabetes should talk with their doctors about whether Ozempic® is right for them,” said Ed Cinca, Senior Vice President, Marketing & Patient Solutions at Novo Nordisk Inc. “With our campaign, we’re cutting through the noise with straightforward education about how Ozempic® fits into care. Ozempic® is the only FDA-approved GLP-1 that improves blood sugar along with diet and exercise and reduces the risk of major cardiovascular events and worsening kidney disease - key information that can make a real difference when choosing a type 2 diabetes treatment.”

The “There’s Only One Ozempic®” campaign uses relatable storytelling and well-known voices to help information stand out in a crowded category and encourages people to look beyond surface-level familiarity with GLP-1s, seek credible information, and have more significant conversations about which FDA-approved treatments for type 2 diabetes may be right for them.

This new consumer campaign is educating patients on the differences between GLP-1s and underscoring Novo Nordisk’s commitment to keeping them at the center. With the most FDA-approved uses among GLP-1s for type 2 diabetes, Ozempic® is an injectable prescription medicine used to improve blood sugar along with diet and exercise for adults with type 2 diabetes, to reduce the risk of major cardiovascular events (heart attack, stroke, or death) in adults with type 2 diabetes and known heart disease, and to reduce the risk of worsening kidney disease, kidney failure (end-stage kidney disease), and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease. Ozempic® is not approved for use in children. Given the vast amount of information on knock-off or compounded “semaglutide” being shared in the media, it is important for healthcare professionals and patients to have the clarity and confidence in knowing what they are using has undergone rigorous review for safety, effectiveness, and quality. Only Novo Nordisk manufactures FDA-approved semaglutide medicines, like Ozempic®. If the label doesn't say Ozempic®, it's not FDA-approved.

“Humor has a way of opening the door to conversations people might otherwise avoid,” said Justin Long. “This campaign uses that idea thoughtfully and meets people where they are consuming content while helping them feel comfortable enough to learn more about their health.” John Hodgman added, “It's important for people to learn more about their medication options and have that discussion with their doctors. What I appreciate about this campaign is the way it encourages meaningful conversations that can truly make a difference.” Justin Long and John Hodgman are paid spokespeople for Novo Nordisk, and they do not live with type 2 diabetes, or take Ozempic®.